GOODRX REPORTS THIRD QUARTER 2025 RESULTS

Company Maintains Full Year 2025 Revenue and Adjusted EBITDA Expectations;

Raises Pharma Manufacturer Solutions Revenue Outlook to Approximately 35% Year-Over-Year Growth for 2025

SANTA MONICA, Calif. -- (November 4, 2025) -- GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or

the “Company”), the leading platform for medication savings in the U.S., has released its financial results for the third quarter

of 2025.

Third Quarter 2025 Highlights

•Revenue of $196.0 million

•Net income of $1.1 million; Net income margin of 0.6%

•Adjusted Net Income1 of $28.8 million; Adjusted Net Income Margin1 of 14.7%

•Adjusted EBITDA1 of $66.3 million; Adjusted EBITDA Margin1 of 33.8%

•Net cash provided by operating activities of $76.0 million

“GoodRx delivered another quarter of strong execution and meaningful progress across our strategic priorities,” said Wendy

Barnes, Chief Executive Officer and President of GoodRx. “We expanded our manufacturer partnerships, launched

innovative pharmacy counter solutions, and strengthened our brand as the most trusted name in prescription access and

affordability. We also engaged meaningfully with the Presidential administration, helping to inform policy efforts that expand

access and affordability for all Americans. Even amid a dynamic healthcare environment, our platform continues to

demonstrate its power and relevance, delivering real value to consumers, pharmacies, and manufacturers, and positioning

GoodRx for sustainable, long-term growth.”

1Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, and Adjusted Net Income Margin are non-GAAP financial measures and are presented for

supplemental informational purposes only. Adjusted EBITDA Margin and Adjusted Net Income Margin are defined as Adjusted EBITDA and Adjusted Net

Income, respectively, divided by Adjusted Revenue. Refer to the Non-GAAP Financial Measures section below for definitions, additional information, and

reconciliations to the most directly comparable GAAP measures.

Third Quarter 2025 Financial Overview (all comparisons are made to the same period of the prior year unless otherwise

noted):

Revenue increased to $196.0 million compared to $195.3 million.

Prescription transactions revenue decreased 9% to $127.3 million compared to $140.4 million, primarily driven by a

decrease in the number of our Monthly Active Consumers, due to the broader changes in the retail pharmacy landscape,

including store closures, and volume reduction in one of our integrated savings programs, partially offset by improved unit

economics related to contracting with certain of our customers and partners and favorable changes in sales mix.

Subscription revenue decreased 3% to $20.7 million compared to $21.3 million, primarily driven by a decrease in the

number of our subscription plans.

Pharma manufacturer solutions revenue increased 54% to $43.4 million compared to $28.1 million, driven by organic growth

as we continued to expand our market penetration with pharma manufacturers and other customers, including ongoing

growth in our consumer direct pricing (previously described as point of sale discount programs).

Net income was $1.1 million compared to $4.0 million. Net income margin was 0.6% compared to 2.0%. Adjusted Net

Income1 was $28.8 million compared to $31.9 million.

Adjusted EBITDA1 was $66.3 million compared to $65.0 million. Adjusted EBITDA Margin1 was 33.8% compared to 33.3%.

Cash Flow and Capital Allocation

Net cash provided by operating activities in the third quarter was $76.0 million compared to $86.9 million in the comparable

period last year. As of September 30, 2025, we had cash and cash equivalents of $273.5 million and total outstanding debt

of $496.3 million.

We are focused on a disciplined approach to capital allocation, centered on furthering our mission and creating shareholder

value. Our capital allocation priorities are investing for profitable growth, paying down debt, buying back shares, and M&A

that aligns with our strategic priorities. These capital allocation priorities support our long-term growth strategy while also

providing flexibility to navigate near-term challenges.

Share Repurchases

During the third quarter of 2025, we repurchased 13.4 million shares of Class A common stock for an aggregate of $61.6

million. As of September 30, 2025, we had $81.4 million of unused authorized share repurchase capacity under our $450.0

million share repurchase program, which does not have an expiration date.

Guidance

For the full year 2025, management is anticipating the following:

“GoodRx delivered a solid financial quarter and strong execution across our key initiatives,” said Chris McGinnis, Chief

Financial Officer and Treasurer of GoodRx. “Total revenue of $196 million increased slightly versus the prior year, with

pharma manufacturer solutions seeing 35% growth year-to-date when compared to the first nine months of 2024.”

“Looking ahead, we are reaffirming our full-year 2025 revenue and Adjusted EBITDA2 guidance,” continued McGinnis.

“While we expect fourth quarter revenue to decline sequentially due to the timing of certain manufacturer deals that closed

earlier than anticipated, we believe our fundamentals remain strong. We are executing with discipline, maintaining a healthy

balance sheet, and continuing to focus on driving profitable growth and long-term value creation.”

2Adjusted EBITDA Margin is Adjusted EBITDA divided by Adjusted Revenue. Adjusted EBITDA and Adjusted EBITDA Margin are non-GAAP financial

measures and are presented for supplemental informational purposes only. We have not reconciled our Adjusted EBITDA and Adjusted EBITDA Margin

guidance to GAAP net income or loss and GAAP net income or loss margin, respectively, because we do not provide guidance for such GAAP measures due

to the uncertainty and potential variability of stock-based compensation expense, acquired intangible assets and related amortization and income taxes, which

are reconciling items between Adjusted EBITDA and Adjusted EBITDA Margin and their respective most directly comparable GAAP measures. Because such

items cannot be provided without unreasonable efforts, we are unable to provide a reconciliation of the non-GAAP financial measure guidance to the

corresponding GAAP measure. However, such items could have a significant impact on our future GAAP net income or loss and GAAP net income or loss

margin.

Investor Conference Call and Webcast

GoodRx management will host a conference call and webcast tomorrow, November 5, 2025, at 5:00 a.m. Pacific Time (8:00

a.m. Eastern Time) to discuss the results and the Company’s business outlook.

To participate via telephone, please call (800) 715-9871 at least 10 minutes before the conference call is scheduled to begin.

The conference ID is 9085550.

The call will also be webcast live on the Company’s investor relations website at https://investors.goodrx.com, where

accompanying materials will be posted prior to the conference call.

Approximately one hour after completion of the live call, an archived version of the webcast will be available on the

Company’s investor relations website at https://investors.goodrx.com for at least 30 days.

About GoodRx

GoodRx is the leading platform for medication savings in the U.S., used by nearly 30 million consumers and over one million

healthcare professionals annually. Uniquely situated at the center of the healthcare ecosystem, GoodRx connects

consumers, healthcare professionals, payers, pharmacy benefit managers, pharmaceutical manufacturers, and retail

pharmacies to make saving on medications easier. By reducing friction and inefficiencies, GoodRx helps consumers save

time and money when filling prescriptions so they can get the care they deserve. Since 2011, GoodRx has helped

Americans save over $85 billion on the cost of their medications.

GoodRx periodically posts information that may be important to investors on its investor relations website at https://

investors.goodrx.com. We intend to use our website as a means of disclosing material non-public information and for

complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are

encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press

releases, filings with the Securities and Exchange Commission and public conference calls and webcasts. The information

contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of,

this press release.

Investor Contact

GoodRx

Aubrey Reynolds

ir@goodrx.com

Press Contact

GoodRx

Lauren Casparis

lcasparis@goodrx.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of

1995. All statements contained in this press release that do not relate to matters of historical fact should be considered

forward-looking statements, including without limitation statements regarding our future results of operations and financial

position, industry and business trends, including uncertainty in the macro environment, the impact of retail store closures

and bankruptcies on our future financial results, the potential impact of the new government sponsored direct-to-consumer

platform called “TrumpRx.gov” and other evolving federal initiatives, our value proposition, consumer and partner perception

and our position in the healthcare ecosystem/industry, our integrated savings programs, the impact of recent volume

reduction in the program with a certain PBM partner, our business strategy and our ability to execute on our strategic

priorities and value creation, our plans, market opportunity, strategic initiatives and long-term growth prospects, our capital

allocation priorities, the anticipated expansion of our condition-specific subscription program and our ability to expand our

offerings through partnerships with pharmaceutical companies. These statements are neither promises nor guarantees, but

involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance

or achievements to be materially different from any future results, performance or achievements expressed or implied by the

forward-looking statements, including, but not limited to, risks related to our limited operating history and early stage of

growth; our recent growth rates may not be sustainable or indicative of future growth; our ability to achieve broad market

education and change consumer purchasing habits; our general ability to continue to attract, acquire and retain consumers

in a cost-effective manner; our significant reliance on our prescription transactions offering and ability to expand our

offerings; changes in medication pricing and the significant impact of pricing structures negotiated by industry participants;

our general inability to control the categories and types of prescriptions for which we can offer savings or discounted prices;

our reliance on a limited number of industry participants, including pharmacy benefit managers, pharmacies, and pharma

manufacturers; the competitive nature of our industry; risks related to pandemics, epidemics or outbreak of infectious

disease; the accuracy of our estimate of our addressable market and other operational metrics; our ability to respond to

changes in the market for prescription pricing and to maintain and expand the use of GoodRx codes; our ability to maintain

positive perception of our platform or maintain and enhance our brand; risks related to any failure to maintain effective

internal control over financial reporting; risks related to use of social media, emails, text messages and other messaging

channels as part of our marketing strategy; our dependence on our information technology systems and those of our third-

party vendors, and risks related to any failure or significant disruptions thereof; risks related to government regulation of the

internet, e-commerce, consumer data and privacy, information technology and cybersecurity; risks related to the use of AI

and machine learning in our business; risks related to a decrease in consumer willingness to receive correspondence or any

technical, legal or any other restrictions to send such correspondence; risks related to any failure to comply with applicable

data protection, privacy and security, advertising and consumer protection laws, regulations, standards, and other

requirements; our ability to utilize our net operating loss carryforwards and certain other tax attributes; the risk that we may

be unable to realize expected benefits from our restructuring and cost reduction efforts; our ability to attract, develop,

motivate and retain well-qualified employees; risks related to our acquisition strategy; risks related to our debt arrangements;

interruptions or delays in service on our apps or websites or any undetected errors or design faults; our reliance on third-

party platforms to distribute our platform and offerings, including software as-a-service technologies; systems failures or

other disruptions in the operations of these parties on which we depend; risks related to climate change; the increasing

focus on environmental sustainability and social initiatives; risks related to our intellectual property; risks related to operating

in the healthcare industry; risks related to our organizational structure; litigation related risks; our ability to accurately

forecast revenue and appropriately plan our expenses in the future; risks related to general economic factors, natural

disasters or other unexpected events; risks related to fluctuations in our tax obligations and effective income tax rate which

could materially and adversely affect our results of operations; risks related to the healthcare reform legislation and other

proposed or future changes impacting the healthcare industry and healthcare spending which may adversely affect our

business, financial condition and results of operations; as well as the other important factors discussed in the section entitled

“Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as updated by our Quarterly

Report on Form 10-Q for the three months ended September 30, 2025, and in our other filings with the Securities and

Exchange Commission. The forward-looking statements in this press release are based upon information available to us as

of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such

information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an

exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain

and investors are cautioned not to unduly rely upon these statements. While we may elect to update such forward-looking

statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to

change.

Key Operating Metrics

Monthly Active Consumers (MACs) refers to the number of unique consumers who have used a GoodRx code to purchase a

prescription medication in a given calendar month and have saved money compared to the list price of the medication. A

unique consumer who uses a GoodRx code more than once in a calendar month to purchase prescription medications is

only counted as one Monthly Active Consumer in that month. A unique consumer who uses a GoodRx code in two or three

calendar months within a quarter will be counted as a Monthly Active Consumer in each such month. Monthly Active

Consumers do not include subscribers to our subscription offerings, consumers of our pharma manufacturer solutions

offering, or consumers who use our telehealth offering. When presented for a period longer than a month, Monthly Active

Consumers are averaged over the number of calendar months in such period. Monthly Active Consumers from acquired

companies are only included beginning in the first full quarter following the acquisition. Effective January 1, 2025, Monthly

Active Consumers from acquired companies are included beginning from the acquisition date. Prior to January 1, 2025,

Monthly Active Consumers from acquired companies were only included beginning in the first full quarter following the

acquisition. As our business continues to evolve, we are reassessing the Monthly Active Consumers metric as a primary

indicator of performance to ensure it aligns with how we measure growth and profitability.

Subscription plans represent the ending subscription plan balance across our subscription offerings, GoodRx Gold, Kroger

Savings Club (sunset in July 2024), condition-specific related subscription programs (first launched in June 2025), and

RxSmartSaver+ powered by GoodRx (launched in July 2025). For GoodRx Gold, Kroger Savings Club, and

RxSmartSaver+, each subscription plan may represent more than one subscriber since family subscription plans may

include multiple members.

We exited the third quarter of 2025 with over 6 million prescription-related consumers that used GoodRx across our

prescription transactions and subscription offerings. Our prescription-related consumers represent the sum of Monthly Active

Consumers for the three months ended September 30, 2025 and subscribers to our subscription plans as of September 30,

2025.

Condensed Consolidated Balance Sheets (Unaudited)

Condensed Consolidated Statements of Operations (Unaudited)

Condensed Consolidated Statements of Cash Flows (Unaudited)

For the three and nine months ended September 30, 2025 and 2024, revenue comprised of the following:

Non-GAAP Financial Measures

Adjusted Revenue and metrics presented as a percentage of Adjusted Revenue, Adjusted EBITDA, Adjusted EBITDA

Margin, Adjusted Net Income, Adjusted Net Income Margin and Adjusted Earnings Per Share are supplemental measures of

our performance that are not required by, or presented in accordance with, U.S. GAAP. We also present each cost and

operating expense on our condensed consolidated statements of operations on an adjusted basis to arrive at adjusted

operating income. Collectively, we refer to these non-GAAP financial measures as our “Non-GAAP Measures."

We define Adjusted Revenue for a particular period as revenue excluding client contract termination costs associated with

restructuring related activities. We exclude these costs from revenue because we believe they are not indicative of past or

future underlying performance of the business. For the three and nine months ended September 30, 2025 and full year

2024, revenue was equal to Adjusted Revenue. In addition, we expect revenue for the full year of 2025 to equal Adjusted

Revenue.

We define Adjusted EBITDA for a particular period as net income or loss before interest, taxes, depreciation and

amortization, and as further adjusted for, as applicable for the periods presented, acquisition related expenses, stock-based

compensation expense, payroll tax expense related to stock-based compensation, loss on extinguishment of debt, financing

related expenses, loss on operating lease assets, restructuring related expenses, legal settlement expenses, gain on sale of

business, and other income or expense, net. Adjusted EBITDA Margin represents Adjusted EBITDA as a percentage of

Adjusted Revenue.

We define Adjusted Net Income for a particular period as net income or loss adjusted for, as applicable for the periods

presented, amortization of intangibles related to acquisitions and restructuring activities, acquisition related expenses, stock-

based compensation expense, payroll tax expense related to stock-based compensation, loss on extinguishment of debt,

financing related expenses, loss on operating lease assets, restructuring related expenses, legal settlement expenses, gain

on sale of business, other income or expense, net, and as further adjusted for estimated income tax on such adjusted items.

Our adjusted taxes also excludes (i) the valuation allowance recorded against certain of our net deferred tax assets that was

recognized in accordance with GAAP and any subsequent releases of the valuation allowance, and (ii) all tax benefits/

expenses resulting from excess tax benefits/deficiencies in connection with stock-based compensation. Adjusted Net

Income Margin represents Adjusted Net Income as a percentage of Adjusted Revenue.

Adjusted Earnings Per Share is Adjusted Net Income attributable to common stockholders divided by weighted average

number of shares. The weighted average shares we use in computing Adjusted Earnings Per Share – basic is equal to our

GAAP weighted average shares – basic and the weighted average shares we use in computing Adjusted Earnings Per

Share – diluted is equal to either GAAP weighted average shares – basic or GAAP weighted average shares – diluted,

depending on whether we have adjusted net loss or adjusted net income, respectively.

We also assess our performance by evaluating each cost and operating expense on our condensed consolidated

statements of operations on a non-GAAP, or adjusted, basis to arrive at adjusted operating income. The adjustments to

these cost and operating expense items include, as applicable for the periods presented, acquisition related expenses,

amortization of intangibles related to acquisitions and restructuring activities, stock-based compensation expense, payroll

tax expense related to stock-based compensation, financing related expenses, restructuring related expenses, legal

settlement expenses, loss on operating lease assets, and gain on sale of business. Adjusted operating income is Adjusted

Revenue less non-GAAP costs and operating expenses.

We believe our Non-GAAP Measures are helpful to investors, analysts and other interested parties because they assist in

providing a more consistent and comparable overview of our operations across our historical financial periods. Adjusted

Revenue, Adjusted EBITDA and Adjusted EBITDA Margin are also key measures we use to assess our financial

performance and are also used for internal planning and forecasting purposes. In addition, Adjusted Revenue, Adjusted

EBITDA, Adjusted EBITDA Margin, Adjusted Net Income and Adjusted Earnings Per Share are frequently used by analysts,

investors and other interested parties to evaluate and assess performance.

The Non-GAAP Measures are presented for supplemental informational purposes only and should not be considered as

alternatives or substitutes to financial information presented in accordance with GAAP. These measures have certain

limitations in that they do not include the impact of certain costs that are reflected in our condensed consolidated statements

of operations that are necessary to run our business. Other companies, including other companies in our industry, may not

use these measures or may calculate these measures differently than as presented herein, limiting their usefulness as

comparative measures.

The following table presents a reconciliation of net income, the most directly comparable financial measure calculated in

accordance with GAAP, to Adjusted EBITDA, and presents net income margin, the most directly comparable financial

measure calculated in accordance with GAAP, with Adjusted EBITDA Margin:

The following tables present a reconciliation of net income and calculations of net income margin and earnings per share,

the most directly comparable financial measures calculated in accordance with GAAP, to Adjusted Net Income, Adjusted Net

Income Margin, and Adjusted Earnings Per Share, respectively:

The following table presents (i) each non-GAAP, or adjusted, cost and expense and operating income measure together with

its most directly comparable financial measure calculated in accordance with GAAP; and (ii) each adjusted cost and

expense and adjusted operating income as a percentage of Adjusted Revenue together with each GAAP cost and expense

and operating income as a percentage of revenue, the most directly comparable financial measure calculated in accordance

with GAAP:

The following table presents a reconciliation of each non-GAAP, or adjusted, cost and expense and operating income

measure to its most directly comparable financial measure calculated in accordance with GAAP: